ArticleNature communications2021
Proteolysis-targeting chimera against BCL-X
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 54 citations in OpenAlex.
- Repurposing BH3 mimetics to deplete tumour-infiltrating regulatory T cells and enhance anti-tumour immunity in non-small cell lung cancer.Cell death and differentiation · 2026Article
- Genetically modulating the RNA-binding protein Regnase-1 reveals its critical role in regulatory T cell homeostasis and function in vivo.Cell death & disease · 2026Article
- PROTAC-based protein degradation: a window of opportunity for melanoma therapy.Journal of biomedical science · 2026Review
- Proteolysis-targeting chimera (PROTAC) nanomedicines toward cancer treatment: From synthesis to therapeutic delivery.Biomaterials · 2026Review
- PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models.Journal of experimental & clinical cancer research : CR · 2026Article
- Targeted protein degradation dismantles undruggable targets to reverse immune evasion and therapy resistance in cancer.Frontiers in immunology · 2026Review
- Targeting the chemokine-Treg axes in tumor immune evasion: from mechanisms to therapeutic opportunities.Frontiers in immunology · 2026Review
- A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model.Oncogene · 2025Article
- Targeted protein degradation with small molecules for cancer immunotherapy.Asian journal of pharmaceutical sciences · 2025Review
- Dual Targeting of Aurora-A and Bcl-xL Synergistically Reshapes the Immune Microenvironment and Induces Apoptosis in Breast Cancer.Cancer science · 2025Article
- Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors.Molecular cancer · 2025Article
- Advancing brain tumor therapy: unveiling the potential of PROTACs for targeted protein degradation.Cytotechnology · 2025Review
- Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets.Histopathology · 2025Review
- A Conversation with ChatGPT on Contentious Issues in Senescence and Cancer Research.Molecular pharmacology · 2024Article
- Role of YY1 in the Regulation of Anti-Apoptotic Gene Products in Drug-Resistant Cancer Cells.Cancers · 2023Review
- Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy.Life medicine · 2023Review
- Protein degraders enter the clinic - a new approach to cancer therapy.Nature reviews. Clinical oncology · 2023Review
- Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy.Pharmaceutics · 2023Review
- BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.Frontiers in oncology · 2023Article
- Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis.Cancer chemotherapy and pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 1 country.
Ryan Kolb *Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Umasankar De *Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Sajid KhanDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID 0000-0003-1331-8846
Yuewan LuoDepartment of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Myung-Chul KimDepartment of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Haijun YuDepartment of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Chaoyan WuDepartment of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Jiao MoDepartment of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Xin ZhangDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Peiyi ZhangDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Xuan ZhangDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID 0000-0001-6062-6708
Nicholas BorcherdingDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
Daniel KoppelUniversity of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA.
Yang-Xin FuDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-4809-825X
Song Guo ZhengDepartment of Internal Medicine, Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH, USA.
Dorina AvramUniversity of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA.
Guangrong ZhengUniversity of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-8106-6663
Daohong ZhouUniversity of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA. zhoudaohong@cop.ufl.edu.ORCID 0000-0002-2400-6461
Weizhou ZhangDepartment of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA. zhangw@ufl.edu.ORCID 0000-0002-8236-0346
University of Florida · USUniversity of Florida Health · USThe Ohio State University Wexner Medical Center · USThe University of Texas Southwestern Medical Center · USUniversity of Iowa · US
Funding
Role of Bcl11b in CD4+ T cells and innate lymphoid cellsR01AI067846 · NIAID · UNIVERSITY OF FLORIDA · PI AVRAM, DORINA · 2007 to 2023
$6.2MUse of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancerR01CA242003 · NCI · UNIVERSITY OF FLORIDA · PI TREVINO, JOSE G., ZHENG, GUANGRONG · 2019 to 2023
$2.6MProteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasisR01CA260239 · NCI · UNIVERSITY OF FLORIDA · PI ZHANG, WEIZHOU · 2021 to 2025
$2.5MRole of Senescent Cells in Radiation-induced Pulmonary FibrosisR01CA219836 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI ZHOU, DAOHONG · 2017 to 2021
$1.8MObesity, inflammation and breast cancerR01CA200673 · NCI · UNIVERSITY OF IOWA · PI ZHANG, WEIZHOU · 2016 to 2020
$1.7MCD177 suppresses breast-cancer development by inhibiting beta-cateninR01CA203834 · NCI · UNIVERSITY OF IOWA · PI ZHANG, WEIZHOU · 2016 to 2020
$1.7MThe role of paracrine WNT5A/RYK in ErbB2-driven tumorigenesisF30CA206255 · NCI · UNIVERSITY OF IOWA · PI BORCHERDING, NICHOLAS · 2017 to 2020
$143kNCI NIH HHS F30 CA206255NCI NIH HHS R01 CA200673NCI NIH HHS R01 CA203834NCI NIH HHS R01 CA219836NCI NIH HHS R01 CA242003NCI NIH HHS R01 CA260239NIAID NIH HHS R01 AI067846
Abstract
Regulatory T cells (Tregs) play an important role in maintaining immune homeostasis and, within tumors, their upregulation is common and promotes an immunosuppressive microenvironment. Therapeutic strategies that can eliminate Tregs in the tumor (i.e., therapies that do not run the risk of affecting normal tissues), are urgently needed for the development of cancer immunotherapies. Here we report our discovery of B-cell lymphoma extra-large (BCL-X
Indexed as
Animalsbcl-X ProteinCells, CulturedCell SurvivalCRISPR-Cas SystemsFemaleFlow CytometryImmunoblottingLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLProteolysisT-Lymphocytes, Regulatorybcl-X Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.